Jade Biosciences filings document a Nasdaq-listed clinical-stage biotechnology issuer developing antibody therapies for autoimmune diseases. Form 8-K reports furnish operating and financial results and attach corporate updates covering JADE101, JADE201, JADE301, research progress, and liquidity-related disclosures.
The company's proxy and material-event filings cover annual meeting matters, board and officer changes, compensatory arrangements, employment inducement stock plans, material agreements, private placement securities, common stock and pre-funded warrant terms, and other capital-structure disclosures. The filings also identify Jade as an emerging growth company with common stock registered under the Exchange Act.
Jade Biosciences, Inc. is seeking stockholder action at its virtual 2026 Annual Meeting on June 9, 2026, including election of two Class II directors, ratification of PricewaterhouseCoopers LLP as auditor and approval of an amendment to waive jury trials for certain "internal actions."
The proxy summarizes the April 28, 2025 business combination that created the current Jade structure; immediately after the Merger, Pre-Merger Jade securityholders owned approximately 98.6% of the company on a fully diluted basis and Aerovate securityholders owned approximately 1.4%. Shares outstanding were 49,316,287 as of March 15, 2026, and the record date for voting is April 17, 2026.
Jade Biosciences, Inc. reported that its Board of Directors approved the 2026 Employment Inducement Stock Incentive Plan. The plan is intended for new employees as an inducement to join the company, in line with Nasdaq Listing Rule 5635(c)(4).
The Board initially reserved 1,750,000 shares of common stock for awards under the plan. It is substantially similar to the company’s 2025 Stock Incentive Plan, but it does not permit incentive stock options and may only grant awards to eligible recipients under applicable Nasdaq rules.
Jade Biosciences, Inc. filed a Post-Effective Amendment No. 1 to its Form S-1 to furnish the consent of PricewaterhouseCoopers LLP dated March 6, 2026. The consent relates to PwC's report on the financial statements in the Form 10-K for the year ended December 31, 2025 and the Prospectus Supplement No. 1 dated March 6, 2026. The Amendment becomes effective upon filing under Rule 462(d).
Jade Biosciences, Inc. filed a Post-Effective Amendment No. 1 to its Form S-1 under Rule 462(d) to include the consent of PricewaterhouseCoopers LLP dated March 6, 2026 relating to the financial statements in its Annual Report on Form 10-K for the year ended December 31, 2025 and in Prospectus Supplement No. 1 dated March 6, 2026.
Jade Biosciences, Inc. files a prospectus supplement to update its offering materials and incorporates key disclosures from its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
The prospectus supplement states the company’s common stock trades on Nasdaq under the symbol JBIO, with a last reported sale price of $13.88 per share on March 5, 2026. The Form 10-K reports 49,316,287 shares outstanding as of February 28, 2026 and an aggregate market value held by non-affiliates of approximately $289.4 million as of June 30, 2025. The Form 10-K describes Jade’s pipeline (lead candidate JADE101 in Phase 1 for IgA nephropathy, planned Phase 2 start in mid-2026), JADE201 plans (Phase 1 planned in Q2 2026), collaboration and license terms with Paragon and third-party manufacturing arrangements.
Jade Biosciences, Inc. files a prospectus supplement to the S-1 registering common stock for resale by a selling stockholder.
The supplement incorporates by reference the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The filing discloses 49,316,287 shares outstanding as of February 28, 2026 and a last reported Nasdaq sale price of $13.88 per share on March 5, 2026.
Jade Biosciences, Inc. describes its business as a clinical-stage biopharmaceutical company focused on novel biologic therapies for autoimmune diseases. The lead antibody, JADE101, targets APRIL for IgA nephropathy, with a Phase 1 trial in healthy volunteers started in August 2025 and a Phase 2 IgAN trial planned for mid-2026.
JADE201, an afucosylated, half-life extended anti-BAFF-R antibody, is being advanced toward a Phase 1 trial in rheumatoid arthritis patients in the second quarter of 2026. A third program, JADE301, targets an undisclosed pathway with a first-in-human trial expected in 2027.
The company outlines a large IgA nephropathy opportunity, citing an FDA-estimated U.S. prevalence of 169,000 patients and a U.S. addressable market of approximately $20 billion, and highlights collaborations and license agreements with Paragon and major biologics manufacturers to support development and manufacturing.
Jade Biosciences reported fourth quarter and full year 2025 results and detailed progress across its autoimmune disease pipeline. The company ended December 31, 2025 with cash, cash equivalents and investments of $336,158 thousand and total assets of $349,781 thousand.
Total liabilities were $17,263 thousand and stockholders’ equity was $332,518 thousand, compared with a deficit a year earlier. For 2025, research and development expenses were $93,121 thousand and general and administrative expenses were $20,421 thousand, leading to a net loss of $127,410 thousand.
The net loss per share attributable to common stockholders was $3.19 basic and diluted. Management highlighted clinical momentum for JADE101 in Phase 1 for IgA nephropathy, plans to start a Phase 2 trial and first-in-human dosing of JADE201, and an expected cash runway extending into the first half of 2028.
Sofinnova-linked funds and principals now report a much smaller stake in Jade Biosciences, Inc. common stock. The group, including Sofinnova Venture Partners X and related entities, beneficially owns 107,391 shares, representing about 0.3% of the company’s common stock based on 32,626,730 shares outstanding as of September 30, 2025.
The update follows the April 28, 2025 merger between Jade Biosciences, Inc. and Aerovate Therapeutics, Inc., preceded by a 1-for-35 reverse stock split. As a result of these corporate actions, the Sofinnova group ceased to own more than 5% of Jade Biosciences’ outstanding common shares but continues to hold its position for investment purposes.
Jade Biosciences, Inc. (JBIO) received an amended Schedule 13G reporting that Venrock Healthcare funds and related entities collectively beneficially own 5,115,862 shares of common stock and pre-funded warrants, representing 9.99% of the company’s common stock as of December 31, 2025.
The holdings are spread across several Venrock vehicles, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and Venrock Healthcare Capital Partners EG, L.P., with management entities and individuals Nimish Shah and Bong Koh having shared voting and dispositive power.
The pre-funded warrants include a “Beneficial Ownership Blocker” that prevents exercise if ownership would exceed 9.99% of Jade Biosciences’ outstanding common stock. The filers certify that the securities are not held for the purpose of changing or influencing control of the company.